A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Summary
- Conditions
- Multiple Sclerosis
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
Participation Requirements
- Age
- Between 18 years and 45 years
- Gender
- Both males and females
Description
Screening: 2 to 21 days before inclusion (Day -21 to Day -2) Institutionalization period: 6 days including 1 treatment day (Day -1 to Day 6, treatment on Day 1) Follow-up: 7-10 days (may be extended) End of study: Day 38 to Day 41 (may be extended) Total study duration: maximum 9 weeks
Screening: 2 to 21 days before inclusion (Day -21 to Day -2) Institutionalization period: 6 days including 1 treatment day (Day -1 to Day 6, treatment on Day 1) Follow-up: 7-10 days (may be extended) End of study: Day 38 to Day 41 (may be extended) Total study duration: maximum 9 weeks
Tracking Information
- NCT #
- NCT02046629
- Collaborators
- Not Provided
- Investigators
- Study Director: Clinical Sciences & Operations Sanofi
Get Well Soon